Skip to main content

Table 4 Prognostic factors for event-free survival (EFS)

From: Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD

 

Univariate analysis

Multivariate analysis

 

p-value

p-value

Hazard Ratio

95 % Confidence Interval

regimen

0.516

0.751

0.907

0.495 - 1.661

gender

0.061

0.372

0.640

0.241 - 1.705

age

0.256

0.896

0.995

0.923 - 1.073

isotype

0.237

0.125

1.339

0.922 - 1.944

ISS

0.003

0.022

1.853

1.092 - 3.143

Post-induction CR/nCR

0.010

0.041

0.307

0.099 - 0.953

Post-induction VGPR

0.077

0.313

1.976

0.526 - 7.424

Post-ASCT CR/nCR

0.002

0.205

0.439

0.123 - 1.567

Post-ACST VGPR

<0.001

0.116

0.275

0.055 - 1.374